Crowe advises 1Q Health on the acquisition of a majority stake in VivaCell

Crowe advised 1Q Health Group (“1Q Health”), a portfolio company of NORD Holding in the field of CDMO for food supplements and pharmaceuticals, on the acquisition of VivaCell Biotechnology GmbH (“VivaCell”), a German contract research organization.

VivaCell is a privately held, contract research organization (CRO) providing specialized in vitro and ex vivo models for the development and demonstration of health-promoting effects of cosmetics, oral and body care products, nutraceuticals, food and beverages, pharmaceuticals, probiotics, natural products and botanicals.

1Q Health is a leading European nutritional supplement and pharmaceutical CDMO and development partner. The company's focus is on supporting dynamic customers throughout the entire product life cycle and beyond, from development and production to logistics and regulatory support. Hard capsules, liquids, powders and tablets are produced under GMP and IFS/FSSC conditions at three state-of-the-art production sites in Germany and Austria. In addition, 1Q Health supports customers with their international marketing and online presence.

VivaCell complements the 1Q Health Group and gives it the opportunity to scientifically prove the health benefits of these products and thus clearly differentiate them from untested competitor products.

The Crowe BPG team (crowe-bpg.de), which was responsible for the financial due diligence and economic advice, consisted of Andreas Hoffmann, WP and Partner (overall management) and Philipp Jans, Senior Associate (Financial). A tax quick check for the transaction was carried out by Dr. Philipp Kruse (tax advisor and managing director).

Source: Deal Advisors by Majunke